Molecular imaging in the management of cervical cancer

Chyong Huey Lai*, Tzu Chen Yen, Koon Kwan Ng

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

Positron emission tomography (PET), magnetic resonance imaging (MRI), and integrated 18-fluorodeoxyglucose (18F-FDG) PET/computed tomography are valuable techniques for assessing prognosis, treatment response after the completion of concurrent chemoradiation, suspicious or documented recurrence, unexplained post therapy elevations in tumor markers, and the response to salvage treatment when managing cervical cancer. However, PET plays a limited role in the primary staging of MRI-defined node-negative patients. Currently, 18F-FDG is still the only tracer approved for routine use, but several novel targeting PET compounds, high-Tesla MRI machines, diffusion-weighted imaging without contrast, and dynamic nuclear polarized-enhanced 13C-MR spectroscopic imaging may hold promising applications.

Original languageEnglish
Pages (from-to)412-420
Number of pages9
JournalJournal of the Formosan Medical Association
Volume111
Issue number8
DOIs
StatePublished - 08 2012
Externally publishedYes

Keywords

  • Cervical cancer
  • MRI
  • Molecular imaging
  • PET
  • PET/CT

Fingerprint

Dive into the research topics of 'Molecular imaging in the management of cervical cancer'. Together they form a unique fingerprint.

Cite this